Eli Lilly Hikes UK Mounjaro Price by Up to 170% After Trump Push for Global Price Rebalancing

The mounjaro price increase announced by Eli Lilly will see UK costs for the weight-loss drug rise by up to 170% starting September 1. The Eli Lilly Mounjaro price increase follows pressure from US President Donald Trump to rebalance medicine prices globally. Mounjaro prices in the UK will now range from £133 to £330 per injection pen, compared to the previous £92 to £122.



US pharmaceutical giant Eli Lilly has sharply increased the UK price of its weight-loss drug Mounjaro, raising costs by up to 170% in response to calls from Donald Trump to address international drug pricing disparities.

From September 1, Mounjaro will cost UK private providers between £133 and £330 per injection pen (containing four doses), compared to the current £92 to £122. While clinics set their own patient prices, costs are expected to rise in line with the higher list price.

Eli Lilly explained the increase as an effort to resolve “pricing inconsistencies compared to other developed countries”, noting that UK prices were previously well below the European average. The company cited new clinical evidence and changes in the market environment as factors in its decision.

The move comes days after President Trump urged pharmaceutical companies to lower drug prices for Americans while charging more in other nations he described as “foreign freeloaders.” In a letter to multiple drugmakers, including GSK and AstraZeneca, Trump insisted that higher overseas revenues should help reduce US patient costs.

The UK’s NHS—known for driving hard bargains on medicine pricing—has reached a confidential agreement with Eli Lilly to ensure continued supply and access for eligible patients. NHS prices are generally lower than private market rates.

Mounjaro is available on the NHS for people with a BMI over 40 plus at least four specified health conditions such as type 2 diabetes and sleep apnoea. Private eligibility starts at a BMI of 30.

This development may signal the start of broader medicine price increases in the UK. Earlier this year, Britain and the US signed a trade agreement in which the NHS committed to reviewing drug prices to consider American concerns.

While NHS funding for eligible obesity and diabetes patients will remain unchanged, those obtaining the drug privately are likely to face higher costs.

An NHS England spokesperson reaffirmed: “Approved list price increases will not affect NHS commissioning of tirzepatide (Mounjaro) for eligible patients.


Relevant Queries:

mounjaro price increase

eli lilly mounjaro price increase

mounjaro

mounjaro price

mounjaro price increase uk

mounjaro uk

eli lilly

mounjaro prices